Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPG0916
- Development stage
- Preclinical
- Lead developer
- Nanjing Immunophage Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
IPG0916 is a monoclonal antibody targeting the C-C chemokine receptor type 6 (CCR6), currently in preclinical development by Nanjing Immunophage Biotech for the treatment of autoimmune diseases. CCR6 is a G protein-coupled receptor predominantly expressed on Th17 cells, regulatory T cells (Tregs), and certain dendritic cells. It plays a pivotal role in the chemotactic migration of these cells to inflammatory sites in response to its ligand, CCL20 (LARC). By binding to CCR6, IPG0916 is designed to block the CCR6-CCL20 axis, thereby inhibiting the recruitment of pathogenic Th17 cells and modulating the inflammatory milieu characteristic of various autoimmune conditions.
02
Targets
CCR6 (C-C motif chemokine receptor 6)
Beyond the preview
Go deeper on IPG0916.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPG0916.